Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF), a leading digital cannabis education and analytics company, is pleased to announce it continues to increase its digital assets, grow traffic to its digital cannabis education platform Cannvas.Me and drive new user sign-ups through the acquisition of nearly 1000 unique domains relating to health and cannabis education, cannabis data and analytics and pet healthcare through cannabis.
“The recent redesign of our corporate website alongside the acquisition of Cannvas.com as a centralized portal for our lineup of products and services underscores our commitment to strategically growing our business as we continue to increase our digital assets to drive site traffic and expand our user base as well as the reach of Cannvas.Me,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech. “Cannvas plans to pursue digital assets aligned with our business goals and strengthen our portfolio of domains to ensure as many people as possible are exposed and interact with the Cannvas brand across Canada and the world.”
In the span of one calendar year, Cannvas has increased its digital assets by 240%, acquiring a total of 835 digital properties designed to increase user flow to Cannvas.Me and accumulate additional data to complement the information already actively analyzed by Cannvas. Multiple domains pointing back at Cannvas.Me also improves search engine optimization (SEO) and Cannvas is focused on ensuring its digital cannabis learning platform ranks high in global searches for cannabis education and related terms.
Since its launch in October 2018, Cannvas.Me has seen consistent month-to-month user growth of 30%, with a spectacular rise of 524% in March of this year. Attributed largely to its aggressive acquisition of strategic domains related to cannabis education, health care and data, Cannvas is now on track to have over 4 million unique users accessing its free and unbiased cannabis education in 2019, with over 50 million views of Cannvas articles and courses before year’s end. This puts Cannvas on track to have over 90% of countries around the world engaging with its content before the end of 2019.
About Cannvas MedTech Inc.
Cannvas MedTech is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.
For further information: firstname.lastname@example.org or visit Cannvas.com
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).
Canopy Growth to Participate in BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.
For more information regarding the Company or the offering, please contact email@example.com, or